The end of Novo Nordisk’s supply problems could bring new headaches for ... Novo says that it has regulatory clearance ...
By Anna Ringstrom and Maggie Fick STOCKHOLM/LONDON (Reuters) -Danish drugmaker Novo Nordisk will invest 8.5 billion crowns ...
Eli Lilly (LLY -1.28%) and Novo Nordisk (NVO 1.03%) have competed for decades. They're both leaders in the areas of insulin ...
The maker of weight-loss and diabetes drugs has supercharged the Danish economy — but other businesses complain that’s left ...
It’s quickly become evident that GLP-1 drugs for diabetes, weight loss, and more are the new wonder drugs—if only people ...
Danish pharmaceutical giant Novo Nordisk, maker of diabetes and weight-loss treatments Ozempic and Wegovy, said Monday it was ...
Eli Lilly said its weight loss drug Zepbound led to 47% greater weight reduction than rival medicine Wegovy, made by Novo ...
Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...
Not just drugs for obesity and diabetes. The Danish pharmaceutical giant differentiates itself in other sectors ...
NVO's CagriSema target of up to 25% in long-term weight loss is highly promising vs. 15% through Wegovy and 20% through ...